NL970006I2 - Gebruik van indolon-derivaten voor het bereiden van geneesmiddelen ter behandeling van de ziekte vanParkinson. - Google Patents

Gebruik van indolon-derivaten voor het bereiden van geneesmiddelen ter behandeling van de ziekte vanParkinson.

Info

Publication number
NL970006I2
NL970006I2 NL970006C NL970006C NL970006I2 NL 970006 I2 NL970006 I2 NL 970006I2 NL 970006 C NL970006 C NL 970006C NL 970006 C NL970006 C NL 970006C NL 970006 I2 NL970006 I2 NL 970006I2
Authority
NL
Netherlands
Prior art keywords
disease
medicines
manufacture
treat parkinson
indolone derivatives
Prior art date
Application number
NL970006C
Other languages
English (en)
Dutch (nl)
Other versions
NL970006I1 (nl
Original Assignee
Smith Kline French Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10617727&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL970006(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smith Kline French Lab filed Critical Smith Kline French Lab
Publication of NL970006I1 publication Critical patent/NL970006I1/nl
Publication of NL970006I2 publication Critical patent/NL970006I2/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
NL970006C 1987-05-21 1997-02-05 Gebruik van indolon-derivaten voor het bereiden van geneesmiddelen ter behandeling van de ziekte vanParkinson. NL970006I2 (nl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB878712073A GB8712073D0 (en) 1987-05-21 1987-05-21 Medicament

Publications (2)

Publication Number Publication Date
NL970006I1 NL970006I1 (nl) 1997-04-01
NL970006I2 true NL970006I2 (nl) 1997-10-01

Family

ID=10617727

Family Applications (1)

Application Number Title Priority Date Filing Date
NL970006C NL970006I2 (nl) 1987-05-21 1997-02-05 Gebruik van indolon-derivaten voor het bereiden van geneesmiddelen ter behandeling van de ziekte vanParkinson.

Country Status (21)

Country Link
US (2) US4824860A (xx)
EP (1) EP0299602B1 (xx)
JP (1) JPH062672B2 (xx)
AT (1) ATE83659T1 (xx)
AU (1) AU599792B2 (xx)
CA (1) CA1305421C (xx)
DE (1) DE3876877T2 (xx)
DK (1) DK169609B1 (xx)
ES (1) ES2052717T3 (xx)
GB (1) GB8712073D0 (xx)
GR (1) GR3007251T3 (xx)
HK (1) HK1000913A1 (xx)
HU (1) HU201871B (xx)
IE (1) IE63511B1 (xx)
LU (1) LU90098I2 (xx)
MX (1) MX9203543A (xx)
NL (1) NL970006I2 (xx)
NZ (1) NZ224709A (xx)
PH (1) PH23867A (xx)
PT (1) PT87542B (xx)
ZA (1) ZA883602B (xx)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9008605D0 (en) * 1990-04-17 1990-06-13 Smith Kline French Lab Process
GB9015095D0 (en) * 1990-07-09 1990-08-29 Smith Kline French Lab Therapeutic method
AU4312593A (en) * 1992-05-18 1993-12-13 Smithkline Beecham Plc Use of indolone derivatives for the treatment of memory disorders, sexual dysfunction and Parkinson's disease
GB9300309D0 (en) * 1993-01-08 1993-03-03 Smithkline Beecham Plc Process
GB9511366D0 (en) * 1995-06-06 1995-08-02 Smithkline Beecham Plc Novel formulations
GB9517062D0 (en) * 1995-08-18 1995-10-25 Scherer Ltd R P Pharmaceutical compositions
US5807570A (en) * 1995-09-29 1998-09-15 Cygnus, Inc. Transdermal administration of ropinirole and analogs thereof
GB9612752D0 (en) * 1996-06-19 1996-08-21 Smithkline Beecham Plc Novel treatment
PT923551E (pt) * 1996-08-27 2002-09-30 American Home Prod Derivados de 4-aminoetoxi indolona
CA2327477A1 (en) * 1998-04-13 1999-10-21 James Albert Nelson 4-amino-(ethylamino)-oxindole dopamine autoreceptor agonists
US6176242B1 (en) 1999-04-30 2001-01-23 Medtronic Inc Method of treating manic depression by brain infusion
US6218421B1 (en) * 1999-07-01 2001-04-17 Smithkline Beecham P.L.C. Method of promoting smoking cessation
AR030557A1 (es) * 2000-04-14 2003-08-27 Jagotec Ag Una tableta en multicapa de liberacion controlada y metodo de tratamiento
US6277875B1 (en) * 2000-07-17 2001-08-21 Andrew J. Holman Use of dopamine D2/D3 receptor agonists to treat fibromyalgia
DE10041478A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
US7858602B2 (en) * 2000-10-16 2010-12-28 Rodriguez Victorio C Therapeutic and prophylactic uses of cell specific carbonic anhydrase enzymes in treating aging disorders due to oxidative stress and as growth factors of stem cells
US6871098B2 (en) * 2000-10-30 2005-03-22 Medtronic, Inc. Method for treating obsessive-compulsive disorder with electrical stimulation of the brain internal capsule
ES2285245T3 (es) * 2002-09-13 2007-11-16 Motac Neuroscience Limited Tratamiento de la disquinesia con 2,3-benzodiazapinas.
AU2003267557B2 (en) * 2002-09-17 2009-02-26 Motac Neuroscience Limited Treatment of dyskinesia
DE10334187A1 (de) * 2003-07-26 2005-03-03 Schwarz Pharma Ag Substituierte 2-Aminotetraline zur Behandlung von Depressionen
DE10334188B4 (de) * 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
WO2005051488A1 (en) * 2003-11-26 2005-06-09 Pfizer Products Inc. Combination of dopamine agonists and monoamine reuptake inhibitors
DE10361258A1 (de) * 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
US7378439B2 (en) * 2004-01-20 2008-05-27 Usv, Ltd. Process for the preparation of 4-(2-dipropylaminoethyl)-1,3-dihydro-2H-indol-2-one hydrochloride
US20050197385A1 (en) * 2004-02-20 2005-09-08 Schwarz Pharma Ag Use of rotigotine for treatment or prevention of dopaminergic neuron loss
DE102004014841B4 (de) * 2004-03-24 2006-07-06 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
WO2007048034A2 (en) * 2005-10-21 2007-04-26 Caritas St. Elizabeth Medical Center Of Boston, Inc. Use of androgens for the treatment of parkinson' s disease
US8475829B2 (en) * 2006-04-06 2013-07-02 Nupathe Inc. Implants for the treatment of dopamine associated states
WO2008001204A2 (en) * 2006-06-29 2008-01-03 Antares Pharma Ipl Ag Transdermal compositions of pramipexole having enhanced permeation properties
TW200815045A (en) * 2006-06-29 2008-04-01 Jazz Pharmaceuticals Inc Pharmaceutical compositions of ropinirole and methods of use thereof
US20090247537A1 (en) * 2008-03-25 2009-10-01 William Dale Overfield Methods for preventing or treating bruxism using dopaminergic agents
CN101574341B (zh) * 2008-05-05 2012-12-19 北京德众万全医药科技有限公司 一种罗匹尼罗的口服固体药物组合物
WO2010023693A2 (en) * 2008-09-01 2010-03-04 Lupin Limited Novel controlled release compositions of ropinirole
CA2738414C (en) 2008-09-29 2014-05-27 Wockhardt Research Centre Extended release dosage form of ropinirole
WO2010044108A2 (en) 2008-10-17 2010-04-22 Rubicon Research Private Limited Controlled release formulations of ropinirole
US20100233259A1 (en) * 2008-12-12 2010-09-16 Pascal Grenier Dosage form of ropinirole
UA103851C2 (xx) 2010-04-30 2013-11-25 ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. Трансдермальна композиція на основі пропіламіноіндану$трансдерамальная композиция на основе пропиламиноиндана
WO2012129429A2 (en) 2011-03-24 2012-09-27 Teikoku Pharma Usa, Inc. Transdermal compositions comprising an active agent layer and an active agent conversion layer
JP5913614B2 (ja) 2011-11-09 2016-04-27 テイコク ファーマ ユーエスエー インコーポレーテッド 皮膚新生物の処置方法
WO2014070622A1 (en) 2012-11-02 2014-05-08 Teikoku Pharma Usa, Inc. Propynylaminoindan transdermal compositions
WO2015168616A1 (en) * 2014-05-02 2015-11-05 Abbvie Inc. Neuronal nicotinic agonists and methods of use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4452808A (en) * 1982-12-07 1984-06-05 Smithkline Beckman Corporation 4-Aminoalkyl-2(3H)-indolones
US4588740A (en) * 1982-12-07 1986-05-13 Smithkline Beckman Corporation Pharmaceutical methods using 4-aminoalkyl-2(3H)-indolones

Also Published As

Publication number Publication date
HK1000913A1 (en) 1998-05-08
NL970006I1 (nl) 1997-04-01
MX9203543A (es) 1992-07-01
AU599792B2 (en) 1990-07-26
EP0299602A2 (en) 1989-01-18
US4912126A (en) 1990-03-27
NZ224709A (en) 1997-02-24
HU201871B (en) 1991-01-28
HUT47217A (en) 1989-02-28
US4824860A (en) 1989-04-25
GR3007251T3 (xx) 1993-07-30
EP0299602A3 (en) 1990-06-06
PT87542B (pt) 1992-09-30
AU1644588A (en) 1988-11-24
PT87542A (pt) 1989-05-31
DK275488A (da) 1988-11-22
EP0299602B1 (en) 1992-12-23
LU90098I2 (fr) 1997-09-25
CA1305421C (en) 1992-07-21
IE63511B1 (en) 1995-05-03
GB8712073D0 (en) 1987-06-24
JPS63303966A (ja) 1988-12-12
ATE83659T1 (de) 1993-01-15
DE3876877T2 (de) 1993-04-29
JPH062672B2 (ja) 1994-01-12
DE3876877D1 (de) 1993-02-04
IE881469L (en) 1988-11-21
ES2052717T3 (es) 1994-07-16
ZA883602B (en) 1989-04-26
DK169609B1 (da) 1994-12-27
PH23867A (en) 1989-11-23
DK275488D0 (da) 1988-05-19

Similar Documents

Publication Publication Date Title
NL970006I2 (nl) Gebruik van indolon-derivaten voor het bereiden van geneesmiddelen ter behandeling van de ziekte vanParkinson.
BR9306841A (pt) Composição farmacêutica processo para proporcionar um tratamento anti-histamínico o qual não induz qualquer arritmia cardíaca significativa em um paciente ser humano e uso de uma composição para a mnaufactura de um medicamento para uso em um tratamento anti-histamínico
NO166448C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive tiazolidindioner.
FI862011A (fi) Terapeutiska nukleosider.
DE3875769T2 (de) Therapeutische nukleoside.
MX9306049A (es) Dinucleotido de nicotinamida-ademina y fosfato de dinucleotido de nicotinamida-adenina como farmacos para tratar la enfermedad de alzheimer.
AU655958B2 (en) Use of quisqualate-receptor antagonists for treating Parkinson's disease
ES2108680T3 (es) Uso del derivado n-n-butilo de desoxinojirimicina en la fabricacion de un medicamento.
DE10299023I2 (de) Antineoplastisch wirkender und den antineoplastischen effekt verstärkender wirkstoff
NO168040C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 3'-demetoksyepipodofyllotoksin-glukosidderivater.
GR3034062T3 (en) Utilization of efaroxan and derivatives thereof for the preparation of a medicament intended to the treatment of parkinson disease
GB8608893D0 (en) D-nor-7-ergoline derivatives
KR890001555A (ko) 요산 배설용 조성물
OA09790A (en) "Paromomycin or its derivatives or salts thereof for parenteral treatment of human parasitic diseases".
EP0202986A3 (en) Use of "naftidrofuryl" in the treatment of neuropathies